Product pharmaceutical-intermediates-nuclide-drug

Home > products > pharmaceutical-intermediates> nuclide-drug

Catalog	name	Description	price
R-M2-10083	Lu-177-PSMA-617	177Lu-PSMA-617 is a radioligand therapy for targeted treatment of prostate cancer, which precisely kills cancer cells by labeling PSMA antigens with beta rays, especially suitable for patients with metastatic castration resistant prostate cancer (mCRPC). Clinical studies have shown that this therapy can significantly prolong patient survival and reduce PSA levels, and suitable patients need to be screened through PSMA PET/CT screening. Multidisciplinary diagnosis and treatment centers have been established domestically to promote standardized application. This product is only for scientific research and cannot be used on the human body.	price>
R-M2-10084	Ga-68-PSMA-I&T	Ga-68-PSMA-I&T is a molecular probe used for the diagnosis of prostate cancer, which achieves precise imaging by targeting prostate-specific membrane antigen (PSMA).	price>
R-M2-10085	Ga-68-PSMA-11	68Ga-PSMA-11 is a radiopharmaceutical used for the diagnosis of prostate cancer, achieving high-sensitivity imaging through targeted binding to prostate-specific membrane antigen (PSMA).	price>
R-M2-10170	68Ga-NOTA-WL12	68Ga-NOTA-WL12 is a peptide based positron emission tomography (PET) imaging agent primarily used for non-invasive evaluation of programmed death ligand 1 (PD-L1) expression in tumor immunotherapy. The probe consists of a targeting peptide WL12 and a chelating agent NOTA, which can specifically bind to PD-L1 positive tumor cells and achieve in vivo visualization imaging by labeling the radioactive nuclide ⁶⁸ Ga. Clinical studies have shown that 68Ga-NOTA-WL12 PET imaging has good safety at acceptable radiation doses, and tumor uptake levels are significantly positively correlated with histological expression of PD-L1 (r=0.9349; P=0.002).	price>

...